Quantitative SPECT/CT imaging of lead-212: a phantom study

por Kvassheim, Monika, Revheim, Mona-Elisabeth R., Stokke, Caroline
Publicado 2022

Correction to: Quantitative SPECT/CT imaging of lead-212: a phantom study

por Kvassheim, Monika, Revheim, Mona-Elisabeth R., Stokke, Caroline
Publicado 2022

Re: Aducanumab-Related ARIA: Paean or Lament?

por Høilund-Carlsen, Poul F., Alavi, Abass, Revheim, Mona-Elisabeth
Publicado 2023

Alzheimer’s Disease at a Crossroad: Time to Part from Amyloid to More Promising Aspects—Atherosclerosis for a Start

por Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Alavi, Abass
Publicado 2022

Inter-reader agreement of (18)F-FDG PET/CT for the quantification of carotid artery plaque inflammation

por Johnsrud, Kjersti, Seierstad, Therese, Russell, David, Revheim, Mona-Elisabeth
Publicado 2020

The value of FDG-PET/CT imaging in the assessment, monitoring, and management of COVID-19

por Griffin, Matthew T., Werner, Thomas J., Alavi, Abass, Revheim, Mona-Elisabeth
Publicado 2023

FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease

por Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Alavi, Abass, Barrio, Jorge R.
Publicado 2023

Can Target-to-Background Ratio Measurement Lead to Detection and Accurate Quantification of Atherosclerosis With FDG PET? Likely Not

por Alavi, Abass, Werner, Thomas J., Høilund-Carlsen, Poul Flemming., Revheim, Mona-Elisabeth
Publicado 2022

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?

por Høilund-Carlsen, Poul F., Werner, Thomas J., Alavi, Abass, Revheim, Mona-Elisabeth
Publicado 2022

Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report

por Lilleby, Wolfgang, Vlatkovic, Ljiljana, Meza-Zepeda, Leonardo A., Revheim, Mona-Elisabeth, Hovig, Eivind
Publicado 2015

(18)F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques

por Johnsrud, Kjersti, Skagen, Karolina, Seierstad, Therese, Skjelland, Mona, Russell, David, Revheim, Mona-Elisabeth
Publicado 2017

FDG PET/CT and Dosimetric Studies of (177)Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?

por Løndalen, Ayca, Blakkisrud, Johan, Revheim, Mona-Elisabeth, Dahle, Jostein, Kolstad, Arne, Stokke, Caroline
Publicado 2022

Imaging of (212)Pb in mice with a clinical SPECT/CT

por Kvassheim, Monika, Tornes, Anna Julie Kjøl, Juzeniene, Asta, Stokke, Caroline, Revheim, Mona-Elisabeth R.
Publicado 2023

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

por Helgebostad, Rasmus, Revheim, Mona-Elisabeth, Johnsrud, Kjersti, Amlie, Kristine, Alavi, Abass, Connelly, James Patrick
Publicado 2022

Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials

por Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Alavi, Abass, Satyamurthy, Nagichettiar, Barrio, Jorge R.
Publicado 2022

Dual targeting with (224)Ra/(212)Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach

por Juzeniene, Asta, Stenberg, Vilde Yuli, Bruland, Øyvind Sverre, Revheim, Mona-Elisabeth, Larsen, Roy Hartvig
Publicado 2023

Monitoring the Effect of Targeted Therapies in a Gastrointestinal Stromal Tumor Xenograft Using a Clinical PET/CT

por Revheim, Mona-Elisabeth, Røe, Kathrine, Bruland, Øyvind Sverre, Bach-Gansmo, Tore, Skretting, Arne, Seierstad, Therese
Publicado 2010

(18)F-FDG and (18)F-NaF PET/CT Global Assessment of Large Joint Inflammation and Bone Turnover in Rheumatoid Arthritis

por Reddy, Natasha, Raynor, William Y., Werner, Thomas J., Baker, Joshua F., Alavi, Abass, Revheim, Mona-Elisabeth
Publicado 2023

Optimization of Q.Clear reconstruction for dynamic (18)F PET imaging

por Lysvik, Elisabeth Kirkeby, Mikalsen, Lars Tore Gyland, Rootwelt-Revheim, Mona-Elisabeth, Emblem, Kyrre Eeg, Hjørnevik, Trine
Publicado 2023

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of (177)Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

por Løndalen, Ayca, Blakkisrud, Johan, Revheim, Mona-Elisabeth, Madsbu, Ulf Erik, Dahle, Jostein, Kolstad, Arne, Stokke, Caroline
Publicado 2020